A Prospective Lifespan Cohort Study of Myocardial Infarction for Building an Integrated Multidimensional Database and Developing an Artificial Intelligence- and Multi-omics-Driven Precision Prevention and Control System
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Enrollment
- 6,000
- Locations
- 1
- Primary Endpoint
- All-cause mortality
Study Overview
Brief Summary
This prospective cohort study aims to establish a lifespan cohort of myocardial infarction and build a standardized, multidimensional, and shareable disease-specific database by systematically integrating clinical phenotypes, multi-omics data, and longitudinal follow-up information. Based on artificial intelligence and multi-omics integration, the study further seeks to develop a precision prevention and control framework for acute myocardial infarction covering the full continuum from early risk warning and accurate diagnosis to individualized treatment and long-term risk management.
The study will enroll adults aged 18 to 74 years, including two major populations: individuals at high risk of acute myocardial infarction, such as those with stable or unstable angina, and patients with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction. Biospecimens, including venous blood, urine, and feces, will be collected, and participants will undergo standardized baseline assessment and follow-up.
The primary outcome is all-cause mortality during follow-up. Secondary outcomes include cardiovascular death, recurrent myocardial infarction, readmission due to heart failure, revascularization, stroke, stent thrombosis, and severe bleeding. This study is expected to provide scientific evidence and technical support for precision prevention, diagnosis, treatment, and long-term management of myocardial infarction.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 74 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Group A (high-risk population):
- •Age 18 to 74 years.
- •Clinically diagnosed with stable angina or unstable angina.
- •Willing to participate in this study and able to provide written informed consent.
- •Able to complete baseline assessment, biospecimen collection, and long-term follow-up.
- •Group B (confirmed acute myocardial infarction population):
- •Age 18 to 74 years.
- •Diagnosed with acute myocardial infarction according to the Fourth Universal Definition of Myocardial Infarction.
- •Time from symptom onset to hospital admission <=24 hours, with patients undergoing emergency percutaneous coronary intervention prioritized.
- •Willing to participate in this study and able to provide written informed consent.
- •Able to complete baseline assessment, biospecimen collection, and long-term follow-up.
Exclusion Criteria
- •End-stage malignant tumor with an expected survival of less than 1 year.
- •Severe hepatic or renal dysfunction, defined as estimated glomerular filtration rate <30 mL/min/1.73 m^2 or Child-Pugh class C.
- •Active autoimmune disease or long-term use of immunosuppressive agents.
- •Pregnant or breastfeeding women.
- •Inability to provide informed consent or severe cognitive impairment.
- •Previous participation in another clinical study that may conflict with this project.
- •Any other condition considered by the investigators to make participation inappropriate.
Arms & Interventions
High-risk Population
Participants at high risk of acute myocardial infarction, including individuals with stable angina or unstable angina, with or without silent myocardial ischemia, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.
Confirmed Acute Myocardial Infarction Population
Participants with confirmed acute myocardial infarction diagnosed according to the Fourth Universal Definition of Myocardial Infarction, including type 1, 2, 3, 4a, 4b, 4c, and 5 myocardial infarction, as well as myocardial infarction with non-obstructive coronary arteries when applicable, who undergo baseline assessment, biospecimen collection, and longitudinal follow-up.
Outcomes
Primary Outcomes
All-cause mortality
Time Frame: From enrollment to the end of study follow-up, up to 5 years
Secondary Outcomes
- Target vessel or non-target vessel revascularization(From enrollment to the end of study follow-up, up to 5 years)
- Stroke(From enrollment to the end of study follow-up, up to 5 years)
- Definite or probable stent thrombosis(From enrollment to the end of study follow-up, up to 5 years)
- Readmission due to heart failure(From enrollment to the end of study follow-up, up to 5 years)
- Cardiovascular death(From enrollment to the end of study follow-up, up to 5 years)
- Recurrent myocardial infarction(From enrollment to the end of study follow-up, up to 5 years)
- Severe bleeding(From enrollment to the end of study follow-up, up to 5 years)
Investigators
Kaiyang Lin
Principal Investigator, Department of Cardiology
Fujian Provincial Hospital